Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Can TTR Assays Track Tafamidis Success in Cardiac Amyloidosis? Can TTR Assays Track Tafamidis Success in Cardiac Amyloidosis?
Pending a practical way to check whether costly tafamidis is working in individuals with TTR amyloid cardiopathy, transthyretin levels just might help as a surrogate efficacy endpoint, researchers propose.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 19, 2021 Category: Cardiology Tags: Cardiology News Source Type: news
MRNA ’s Next Chapter Has Nothing to Do With COVID-19 Vaccines
It’s safe to say that before the development of the Pfizer-BioNTech and Moderna COVID-19 vaccines, most people hadn’t thought about messenger RNA, or mRNA, since high school science class—if ever. The molecule plays a pivotal role in the body, carrying the recipes for making various proteins to the parts of cells that produce them. But “mRNA” wasn’t exactly a common phrase until Pfizer-BioNTech and Moderna harnessed the genetic material’s power to teach the body to make a piece of a protein found on the COVID-19 virus’ surface, thus training it to fight the real thing, were i...
Source: TIME: Health - August 2, 2021 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized healthscienceclimate medicine Source Type: news
MRNA ’s Next Chapter Has Nothing to Do With COVID-19 Vaccines
It’s safe to say that before the development of the Pfizer-BioNTech and Moderna COVID-19 vaccines, most people hadn’t thought about messenger RNA, or mRNA, since high school science class—if ever. The molecule plays a pivotal role in the body, carrying the recipes for making various proteins to the parts of cells that produce them. But “mRNA” wasn’t exactly a common phrase until Pfizer-BioNTech and Moderna harnessed the genetic material’s power to teach the body to make a piece of a protein found on the COVID-19 virus’ surface, thus training it to fight the real thing, were i...
Source: TIME: Science - August 2, 2021 Category: Science Authors: Jamie Ducharme Tags: Uncategorized healthscienceclimate medicine Source Type: news
Johnson & Johnson Reports Q2 2021 Results
New Brunswick, N.J. (July 21, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter. “Our second-quarter results showcase Johnson & Johnson’s diversified portfolio, driven by strong sales and earnings growth across our Medical Device, Consumer Health and Pharmaceutical businesses,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m so proud of our 136,000 colleagues who remain focused on delivering our medicines and products to patients and consumers around the world, in addition to advancing our pipeline with new product launches and regulatory submissions. These ac...
Source: Johnson and Johnson - July 21, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
CRISPR Therapy Fights Rare Disease Where Protein Clogs Organs
TUESDAY, June 29, 2021 -- Early research suggests that CRISPR gene-editing technology may some day lead to dramatic relief for patients struggling with amyloidosis, a rare but serious disease that can trigger organ failure. " There are many... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - June 29, 2021 Category: General Medicine Source Type: news
'A new era of medicine': In a first for CRISPR, Intellia edits cells inside the body
In a first for the still-young field of CRISPR gene editing, Intellia Therapeutics (Nasdaq: NTLA) has successfully edited DNA inside the human body.
The Cambridge biotech, working with Regeneron Pharmaceuticals (Nasdaq: RGEN), genetically altered liver cells in six patients with a genetic nerve disorder called transthyretin amyloidosis in a Phase 1 study. On Saturday, Intellia and Regeneron published data showing that the treatment had reduced levels of a disease-causing protein by 52% at a relatively… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 28, 2021 Category: Pharmaceuticals Authors: Rowan Walrath Source Type: news
Alnylam Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Investigational Vutrisiran for the Treatment of the Polyneuropathy of Hereditary ATTR Amyloidosis
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 24, 2021-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - June 24, 2021 Category: Drugs & Pharmacology Source Type: news
Attralus touts amyloid imaging research at SNMMI 2021
Biopharmaceutical company Attralus is directing attention to research presente...Read more on AuntMinnie.comRelated Reading:
ASNC releases directive on cardiac amyloidosis imaging
JNM: Florbetaben-PET detects cardiac amyloidosis (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 15, 2021 Category: Radiology Source Type: news
Janssen Highlights Commitment to Advancing Transformative Innovations in Oncology with Scientific Updates from Deep, Diverse Pipeline and Portfolio at ASCO and EHA Virtual Scientific Programs
June 1, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 30 company-sponsored studies, including six oral presentations, will be featured during the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, June 4-8. Janssen presentations will include new data and updates for both approved and investigational therapeutics that are being studied for the treatment of various solid tumors and blood cancers. Immediately following ASCO, additional data will be featured during the European Hematology Association (EHA) Virtual Congress, June 9-17. A comp...
Source: Johnson and Johnson - June 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Updated Data Demonstrate Significant Improvement in Hematologic Complete Response with DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
RARITAN, N.J., May 26, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced updated results from the Phase 3 ANDROMEDA study, which evaluated DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare blood cell disorder associated with the deterioration of vital organs, most notably the heart, kidneys and liver.[1] Longer-term results from a median follow-up of 20.3 months showed rates of hematologic complete response (hemCR) remained significantly higher in patients treated with DARZALEX FASPRO® in combi...
Source: Johnson and Johnson - May 26, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Novel Treatment Approach in Transthyretin Amyloidosis Novel Treatment Approach in Transthyretin Amyloidosis
A potential new treatment option aimed at clearing amyloid deposits from vital organs has shown promising preliminary results in an initial clinical trial.Medscape Medical News (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - April 22, 2021 Category: Intensive Care Tags: Neurology & Neurosurgery News Source Type: news
Jonathan Wall receives $1.79 million to develop new amyloidosis treatment
(University of Tennessee Health Science Center) The National Institute of Diabetes and Digestive and Kidney Diseases recently awarded Jonathan Wall, PhD, professor in the University of Tennessee Health Science Center's Graduate School of Medicine in Knoxville, a $1.79 million grant for his study titled " Developing a Theranostic Immunotherapy for Systemic Amyloidosis. " (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 16, 2021 Category: International Medicine & Public Health Source Type: news
Curcumin for amyloidosis and lipid metabolism -- a novel insight
This study demonstrates that curcumin is a PPARα/γ dual activator and may affect expression levels of proteins involved in amyloid deposition and other metabolism functions in a complex manner. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 26, 2021 Category: International Medicine & Public Health Source Type: news
Mayo Clinic Q & amp;A podcast: Symptoms for cardiac amyloidosis overlap with other conditions
Cardiac amyloidosis is irreversible thickening of the heart muscle that typically presents as a form of congestive heart failure. It is overlooked often because the symptoms can masquerade as other conditions. Unfortunately, there aren't any preventive strategies for cardiac amyloidosis, says Dr. Melissa Lyle, a Mayo Clinic cardiologist. "So the key, really, is early detection," says [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - February 19, 2021 Category: Databases & Libraries Source Type: news
